0001628280-26-031751
SEC filingQ1 revenue accelerated 26% to $25.0M on HEPZATO KIT demand, sustaining 85.1% gross margins, but operating loss of $1.6M emerged from SG&A expansion and R&D investments in Phase 2 trials.
Delcath Systems delivered robust Q1 revenue growth of 26.3% to $25.0 million, propelled by sustained demand for the HEPZATO KIT. This uptick directly influenced cost of goods sold, which scaled with sales volume, preserving a strong gross margin of 85.1% and lifting gross profit 25.5% to $21.3 million. The company's supply chain strategy—stockpiling inventory and diversifying suppliers for critical components—ensured sufficient raw materials to meet this demand without disruptions.
Profitability faced headwinds from commercial scaling. Selling, general, and administrative expenses rose due to hiring additional commercial personnel and increased marketing-related travel, contributing to an operating loss of $1.6 million versus prior-year profit of $642 thousand. These investments support broader market penetration for HEPZATO KIT amid ongoing commercial expansion. Net income flipped to a $1.1 million loss, or -$0.03 diluted EPS, underscoring the trade-off between growth initiatives and near-term earnings.